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Abstract
The induction of a broadly neutralizing antibody (BNAb) response against HIV-1 would be a desirable feature of a protective
vaccine. Vaccine strategies thus far have failed to elicit broadly neutralizing antibody responses; however a minority of HIV-
infected patients do develop circulating BNAbs, from which several potent broadly neutralizing monoclonal antibodies
(mAbs) have been isolated. The findings that several BNmAbs exhibit autoreactivity and that autoreactive serum antibodies
are observed in some HIV patients have advanced the possibility that enforcement of self-tolerance may contribute to the
rarity of BNAbs. To examine the possible breakdown of tolerance in HIV patients, we utilized the 9G4 anti-idiotype antibody
system, enabling resolution of both autoreactive VH4-34 gene-expressing B cells and serum antibodies. Compared with
healthy controls, HIV patients had significantly elevated 9G4+ serum IgG antibody concentrations and frequencies of 9G4+ B
cells, a finding characteristic of systemic lupus erythematosus (SLE) patients, both of which positively correlated with HIV
viral load. Compared to the global 9G42IgD2 memory B cell population, the 9G4+IgD2 memory fraction in HIV patients
was dominated by isotype switched IgG+ B cells, but had a more prominent bias toward ‘‘IgM only’’ memory. HIV envelope
reactivity was observed both in the 9G4+ serum antibody and 9G4+ B cell population. 9G4+ IgG serum antibody levels
positively correlated (r=0.403, p=0.0019) with the serum HIV BNAbs. Interestingly, other serum autoantibodies commonly
found in SLE (anti-dsDNA, ANA, anti-CL) did not correlate with serum HIV BNAbs. 9G4-associated autoreactivity is
preferentially expanded in chronic HIV infection as compared to other SLE autoreactivities. Therefore, the 9G4 system
provides an effective tool to examine autoreactivity in HIV patients. Our results suggest that the development of HIV BNAbs
is not merely a consequence of a general breakdown in tolerance, but rather a more intricate expansion of selective
autoreactive B cells and antibodies.
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Introduction
HIV infection is a major global health issue, and there is
a critical need for a protective vaccine. The primary focus for
humoral-mediated protection is the induction of neutralizing
antibodies that recognize the HIV Envelope glycoprotein (Env).
Although antibodies that recognize Env readily develop in HIV-1 -
infected patients and can be induced by vaccination, these
antibodies primarily recognize immunodominant, highly variable
domains [1], consequently conferring little to no protection from
the rapidly evolving virus. A minority of HIV patients develop
serum antibodies that can neutralize a broad range of HIV isolates
[2,3,4]. These broadly neutralizing antibodies (BNAbs) typically
do not arise before three years post-infection [5,6], and their
occurrence correlates with viral load (VL) [2,5,7], suggesting that
long-term antigen-driven evolution of the humoral response may
be required for their development.
The limited incidence of persons producing HIV-reactive
BNAbs in response to infection may in part result from proper
enforcement of immunological tolerance for cross-reactive self-
antigens. A relationship between autoreactive antibody and HIV
BNAb development has been highlighted by several observations.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35356In HIV patients, anti-CL serum antibodies correlate with
increased HIV neutralization breadth [8], and several HIV
broadly neutralizing monoclonal antibodies, including 2F5,
4E10, and 12A21 have been reported to have reactivity to self-
antigens including dsDNA, insulin, Ro, histones, centromere B,
and CL [9,10,11], although this still remains contentious [12,13].
Additionally, many patients with connective tissue autoimmune
disorders, including SLE and anti-phospholipid syndrome (APS),
exhibit limited HIV neutralizing activity [14,15]. Thus, during
normal B cell development, a proportion of B cells with the
potential to give rise to HIV BNAbs may be deleted or rendered
anergic by engagement of corresponding self-antigen, and thus
their development into mature B cells and antibody-secreting cells
may require self-tolerance to be subverted. However, during HIV
infection, substantial B cell hyperactivation manifested by poly-
clonal B cell activation and hypergammaglobulinemia [16], may
contribute to disruption of tolerance, leading to the development
of autoreactive antibodies in HIV patients, including those HIV
BNAbs with autoreactivity. In addition to increases in autoanti-
bodies including anti-CL, anti-dsDNA, anti-nuclear antibodies
(ANA) and others in HIV patients, dramatic alterations in B cell
homeostasis are reflected by the expansion of immature/
transitional B cells, exhausted tissue like-memory B cells [17]
and plasmablasts [18], and decreased resting memory and IgM
memory [16,19]. Many of these serological and cellular alterations
are reversed with anti-retroviral therapy [16], suggesting they
result from ongoing HIV viral replication.
Our group and others previously described an approach to
monitor the development of autoreactive B cells and antibodies in
SLE using the 9G4 anti-idiotype antibody [20,21,22,23]. The rat
anti-human monoclonal antibody 9G4 recognizes VH4-34 (pre-
viously designated VH4-21) -encoded antibodies and the B cells
expressing these antibodies as surface receptor (heretofore referred
to as 9G4+ antibodies and 9G4+ B cells respectively) [24]. Our
laboratory has extensively studied the 9G4 system to understand
human B cell tolerance and its breakdown in SLE [20,25]. The
advantage of the 9G4 system is predicated on a number of unique
and helpful features: 1) 9G4+ antibodies are intrinsically
autoreactive against N-acetylactosamine moietes expressed by
blood group antigens as well as by multiple tissue antigens and
glycoproteins [26,27,28,29], including B220/CD45R which is
expressed by many naı ¨ve B cells [26]. This reactivity is dependent
on the heavy chain framework 1-encoded idiotope recognized by
the 9G4 monoclonal antibody [24,30]. Many 9G4+ antibodies
also cross-react with glycolipids including LPS and gangliosides
and in association with favorable HCDR3s (heavy chain
complementary determining region 3), they may also recognize
DNA [24,31,32]; 2) 9G4+ B cells, despite their autoreactivity,
represent a sizable fraction (5–10%) of the normal repertoire in all
healthy subjects; yet, they are strictly censored from the germinal
centers (GC) and from expanding into the long-lived IgG memory
and plasma cell compartments [33]; 3) such censoring accounts for
the almost complete absence of serum 9G4+ antibodies in healthy
subjects [20,34]; 4) by contrast, GC censoring of 9G4+ B cells is
faulty in SLE and results in large expansions of 9G4+ IgG memory
and plasma cells in these patients [20,34].
In this study, we utilized the 9G4 system to examine both
autoreactive 9G4+ serum antibodies and B cells in HIV patients,
and their relationship with clinical characteristics, HIV reactivity,
and the occurrence of HIV BNAbs.
Materials and Methods
Clinical Samples
Peripheral blood samples were obtained from HIV-1 -infected
patients at the University of Rochester Medical Center and the
University of Washington HIV clinics between 2004 and 2010.
Samples from healthy control (HC) subjects were obtained at the
University of Rochester. All subjects provided signed written
informed consent. Isolated peripheral blood mononuclear cells
and serum were cryopreserved before subsequent analysis. All
procedures and methods were approved by the University of
Rochester Research Subjects Review Board and the University of
Washington Institutional Review Board.
Flow Cytometry
For global B cell phenotypic analysis peripheral blood mono-
nuclear cells (PBMCs) were stained with anti-CD19-APC-Cy7
(SJ25C1, BD), anti-CD20-AlexaFluor 700 (2H7, Biolegend, San
Diego, CA), anti-CD3-PerCP-Cy5.5 (SP34-2, BD), anti-IgD-FITC
(IA6-2, BD), anti-IgG-PE (G18-145, BD), anti-IgM-PE-Cy5 (G20-
127, BD), anti-CD27-Qdot655 (CLB-27/1, Invitrogen), 9G4-
Pacific Blue, and Live/Dead fixable aqua dead cell stain
(Invitrogen). The 9G4 mAb was kindly provided by F.K.
Stevenson (University of Southhampton, Southhampton, United
Kingdom), and recognizes a framework 1 region–encoded idiotype
that is expressed by all unmutated, and close to 90% of mutated
VH4-34 B cells present in the normal repertoire [35–36]. 9G4
painting of B cells was assessed using methods similar to those
previously described [21,26]. Briefly, cells were incubated at either
37uCo r4 uC for 30 minutes in complete media (RPMI 1640+10%
fetal bovine serum), and washed once with PBS, prior to staining
with fluorochrome-conjugated antibodies at 4uC for 60 minutes.
One-to-two million total events per sample were collected on an
LSRII instrument (BD Biosciences) and analysis performed in
a blinded manner using FlowJo software (Treestar, Inc, Ashland,
OR). Total PBMC were gated on lymphocytes using FSC and
SSC. Live/Dead stain and anti-CD3 were used to exclude dead
cells and T cells, respectively.
To measure gp140-specific B cells, PBMC were first incubated
for 30 minutes at 37uC to reduce 9G4 painting, then stained with
purified oligomeric HIV-1 SF162 (clade B) and KNH1144 (clade
A) gp140 directly conjugated to AlexaFluor660 and AlexaFluor
647, respectively and HIV-1 p24 (NIH AIDS Research and
Reference Reagent Program) directly conjugated to Alexa-
Fluor488, in addition to anti-CD19-PE-Cy7, anti-CD20-APC-
Cy7, anti-IgD-PE, anti-IgM-PerCP-Cy5.5, anti-CD3-PE-Cy5,
anti-CD14-PE-Cy5, 7AAD for dead cell exclusion, and biotiny-
lated 9G4 mAb/streptavidin Qdot800 (Invitrogen) at 4uC for
60 minutes. At least one million total CD19+ B cells (<10 million
total PBMC) were analyzed per sample. p24+ gp140+ double-
positive cells, a very rare population, were excluded from the
analysis because they represent B cells that non-specifically react
with gp140.
ELISA
The detection of IgG 9G4+ Abs was performed as previously
described [26]. Briefly, ELISA plates were coated with anti-human
IgG (Jackson ImmunoResearch, West Grove, PA), blocked with
2% nonfat dry milk/2% BSA for 1 h at 37uC, then washed with
0.1% Tween 20 in PBS. Samples were serially diluted in triplicate
in PBS containing 0.01% Tween 20 and 0.5% BSA, and
incubated for 90 minutes at 37uC. Plates were washed, and
binding was detected using biotinylated 9G4 mAb and streptavidin
alkaline phosphatase. A human VH4-34 9G4-reactive mAb,
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and 9G4+ Abs, ELISA plates were coated with purified oligomeric
HIV-1 YU2 gp140 [37] at 2 mg/ml and detected with either
horseradish peroxidase conjugated anti-human IgG (Jackson
ImmunoResearch) or biotinylated 9G4 Ab and streptavidin-
HRP. To detect anti-CL IgG Abs, plates were coated with
50 mg/ml bovine cardiolipin (Sigma) in hexanes, and detected
with anti-IgG HRP. For quantitative purposes the polyclonal
human anti-human CL Ab (Lifespan Biosciences, Seattle, WA)
was used at 1:100 dilution, and assigned a relative units value of
1000, for which all serum samples were normalized to; positive/
negative cutoff was determined as the upper 95% CI for serum
from healthy control subjects. Anti-dsDNA IgG ELISA and Anti-
Nuclear Antigen (ANA) IgG ELISA were performed, testing
samples in duplicate using kits according to manufacturer’s (Inova
Diagnostics, Sand Diego, CA) recommendations.
HIV-1 Neutralizing Activity
The neutralizing activity of sera was determined as previously
described [38]. Briefly, a panel of clade B Tier 1 (SF162) and Tier
2 (6353.3, QH0692.42, SC422661.8, PVO.4, and AC10.0.29)
pseudotyped viruses were incubated with heat-inactivated sera and
then added to TZM-bl indicator cells. SVA-MLV (murine
retrovirus Env-pseudovirus) was included as a negative control to
confirm the absence of anti-retroviral therapy (ART). Neutralizing
antibody titers were determined as the reciprocal serum dilution at
which luciferase expression was reduced by 50% (ID50). To
enable correlative analysis a single, composite BNAb score was
determined using the geometric mean ID50 of the serum Tier 2
neutralizing activity, similar to that previously described [2], and if
the ID50 was ,20 for an individual virus, the value for that virus
was set to 1 to enable calculation.
Statistical Analysis
Two-tailed t test or Mann-Whitney test were used as
appropriate to compare HC and HIV groups. Spearman two-
tailed correlation co-efficient was used to measure the correlation
of two variables. Statistical analyses were performed using Prism
5.0 software (GraphPad Software, La Jolla, CA) and significance
was taken as p,0.05.
Results
HIV-infected patient population
Peripheral blood lymphocytes and serum samples were obtained
from a diverse group of 90 HIV-1 seropositive patients from the
University of Rochester and the University of Washington Center
for AIDS Research (CFAR) cohorts. Most HIV patients (84%) had
no history of anti-retroviral treatment (ART naı ¨ve) and the
remainder were not receiving ART at time of sampling as per
standard of care (Table 1). Samples from HIV-1 -negative healthy
control (HC) subjects were obtained at the University of
Rochester.
HIV patients have elevated 9G4+ serum antibodies and
9G4+ B cells
Increased autoreactive antibodies are frequently observed in
HIV patients, and therefore we asked if this breakdown in
tolerance could be monitored using the 9G4 system as we and
others have previously used for SLE [21,26,33,39]. Indeed, HIV
patients exhibited significant (p,0.01) and approximately 5-fold
greater 9G4+ IgG serum antibody compared with HC subjects
(Fig. 1A), with approximately 40% of HIV patients having 9G4+
IgG serum antibody levels exceeding the 95% CI of HC (not
shown). HIV patients also exhibited a significant (p,0.05) 4-fold
increase in the frequency of 9G4+ total peripheral blood B cells
(Fig. 1B), with approximately 65% of HIV patients exceeding the
95% CI of HC (not shown). These results indicate that increased
9G4+ serum IgG and 9G4+ B cells are commonly found in many,
but not all HIV patients, and are consistent with elevated
autoreactive antibodies previously observed in HIV patients [8].
9G4+ antibody titers and 9G4+ B cell frequencies
correlate with CD4 and viral load in HIV patients
On average, the HIV patients in our study had elevated 9G4+
IgG serum and 9G4+ B cells; however, a substantial continuum
was observed (Fig. 1). To determine what factors might contribute
to the development of 9G4+ IgG serum antibody and 9G4+ B cells
in these patients, regression analysis was performed. Neither age
nor time since HIV diagnosis correlated with 9G4+ serum IgG
antibody or 9G4+ B cell frequency (data not shown). CD4+ T cell
count negatively correlated with 9G4+ IgG serum (r=20.202,
p=0.125) and 9G4+ B cells (r=20.473, p,0.0001) (Fig. 1C+D),
although only reached significance for 9G4+ B cells. HIV VL was
significantly positively correlated with both 9G4+ IgG serum
antibody (r=0.265, p=0.042) and 9G4+ B cells (r=0.374,
p=0.004) (Fig. 1E+F). Interestingly, HIV VL did not correlate
with the abundance of other autoreactive serum antibodies
including anti-dsDNA, ANA, or anti-CL (Fig S1). These results
suggest that HIV viral replication may selectively promote the
development of autoreactive 9G4+ B cells and 9G4+ serum
antibody.
Phenotype of 9G4+ B cells in HIV patients
It is striking that for many HIV patients, greater than 50% of
their total B cell compartment is 9G4+. We previously reported
that in SLE, 9G4+ serum antibodies can bind to B220, which is
expressed on the surface of naı ¨ve B cells and some memory B cells
[26]. This high frequency of 9G4+ B cells in some of the HIV
patients may result from measuring both the B cells actually
expressing VH4-34-encoded BCR, and also the indirect binding of
the 9G4 reagent to serum VH4-34-encoded autoreactive antibody
bound to B220 on the B cell, as previously described in SLE
patients and not HC subjects [21,26] and heretofore referred to as
painting. To determine if 9G4 painting of B cells may be occurring
in HIV patients, samples were incubated at 37uC to dissociate
bound 9G4+ serum antibody prior to 9G4 reagent staining at 4uC.
This approach revealed that similar to SLE [21,26], 9G4 painting
does occur in some HIV patients (Fig. 2A+B), and that soluble
Table 1. HIV-1 patient demographics.
HIV patients (n) 90 range
Age (YR) 41.9+/29.9 22–70
Female (%) 38.6
Time since HIV Dx (YR) 6.3+/25.6 0.1–23.3
ART naı ¨ve (%) 84.1
Non-Caucasian (%) 51.2
Black (%) 48.2
Viral load (copies/ml) 35,500+/2111,629 45–942,000
CD4 (cells/ml) 549+/2237 7–1,080
mean +/2 SD indicated
doi:10.1371/journal.pone.0035356.t001
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proportion of the total B cells. Interestingly, limited longitudinal
sampling (HIV055 and HIV056) indicated that 9G4 painting may
substantially fluctuate over time thereby suggesting episodic
stimulation of 9G4 antibodies rather than steady production
through long-lived plasma cells or continuous B cell stimulation
(Fig. 2B).
By eliminating 9G4 painting, the composition of the actual
9G4+ B cell population in HIV patients was determined (Fig. 2C).
The 9G4+ B cell population in HIV patients was comprised of
Figure 1. 9G4+ serum antibodies and 9G4+ B cells are increased in HIV patients, correlating with CD4 and viral load. Peripheral blood
was collected from ART-negative HIV patients and healthy control (HC) subjects, and serum and PBMC were isolated. A. 9G4+ serum IgG was
determined by ELISA. B. The frequency of 9G4+ B cells was determined by flow cytometry. C–F. Spearmann correlation of 9G4+ serum IgG and 9G4+
B cells with CD4 and VL was determined for HIV patients. Each symbol represents a unique patient. * p,0.05 (Mann Whitney test).
doi:10.1371/journal.pone.0035356.g001
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al (N/T) and IgD+CD27+ unswitched memory B cells (USWM),
and significantly lower frequencies of IgD2CD27+ switched
memory (SWM) B cells and IgD2CD272 double negative (DN) B
cells as compared with the 9G42 B cell population (Fig. 2D).
This observation suggests that 9G4+ B cells may continue to be
partially censored from IgD-memory compartments in HIV
patients, or may reflect the remaining influence of pre-HIV
infection 9G4+ censorship on memory compartment composition.
Because 9G4+ B cells are rare in the IgD2 memory
compartment in HC (Fig S2) [26,33], we infer that IgD29G4+
memory B cells in HIV patients developed in response to HIV
infection and therefore their composition was further assessed.
Within both the 9G4+ and 9G42 fractions of the IgD2 memory
B cell compartment, IgG+ memory cells predominated (Fig. 2E),
at 52% and 46% respectively. Interestingly, within the IgD29G4+
memory compartment, ‘‘IgM only’’ memory (IgG2IgM+CD27+)
was a substantial component compared with the composition of
the IgD29G42 memory compartment, 20% and 6% respectively,
and this difference was significant (p=0.0007). Conversely, a more
prominent IgM2IgG2 population, likely the IgA memory
population, was evident in the IgD29G42 compartment,
compared to the IgD29G4+ compartment, 39% and 9%
respectively, and this difference was significant (p,0.0001). These
differences in the composition of 9G4+ and 9G42 IgD2 memory
compartment may indicate distinct developmental pathways by
which 9G4+ memory B cells cell arise.
HIV Env reactivity of 9G4+ serum antibody and 9G4+ B
cells from HIV patients
Observing the positive correlation of HIV VL and 9G4+ serum
IgG, and considering the autoreactivity of several well-character-
ized HIV Env-specific monoclonal antibodies, we next sought to
determine if 9G4+ serum antibodies are reactive to HIV Env.
YU2gp140-reactive 9G4+ serum antibodies were detected in
many HIV patients (Fig. 3A), although not surprisingly, these
antibodies likely represent only a minority of total YU2gp140-
reactive serum antibodies in HIV patients (Fig. 3B+3C).
However, the amount of Env-reactive 9G4+ serum antibody
may be underestimated by this approach, because binding to Env
may be mediated in part through the specific VH4-34 FR1
idiotope recognized by the 9G4 monoclonal antibody, thus
blocking its detection.
We also conducted Env-specific flow cytometry to identify Env-
reactive 9G4+ memory B cells in HIV patients. 9G4+ Env-reactive
IgD2IgM2 memory B cells were present in HIV patients (Fig. 4).
A mean of <14% of the Env-reactive IgD2IgM2 memory B cells
were 9G4+, whereas 9G4+ cells comprised a mean of only <7% of
the total IgD2IgM2 memory B cells (Fig. 4B). Although this
difference was not statistically significant, it does suggest a selective
expansion of 9G4+ B cells within the Env-reactive B cell repertoire
in some patients. The presence of Env-reactive 9G4+ B cells was
also confirmed by memory B cell EliSpot (Fig S3). These results
suggest that HIV infection promotes the expansion of 9G4+ B cells
and antibodies, a proportion of which are Env-reactive.
9G4+ serum antibody and 9G4+ B cells correlate with
serum HIV broadly neutralizing activity
Given the auto- and Env-reactive properties of 9G4+ antibodies
and B cells, and the rationale that impaired tolerance and
autoreactivity may be advantageous for developing a broadly
neutralizing response against HIV, we assessed the magnitude and
breadth of serum neutralizing activity against a panel of Tier 1 and
Tier 2 clade B isolates (Table S1A). Multi-clade neutralization
was assessed on select samples (Table S1B). To facilitate
regression analysis, we used a composite broadly neutralizing
activity measure, the geometric mean ID50 of the serum Tier 2
clade B neutralizing activity, similar to that previously described
[2]. The samples showed a diverse range of neutralizing activity,
including patients HIV073 and HIV026 (geomean ID50=1555
and 615, respectively), which represent, approximately the top 2%
of all HIV samples tested by the Montefiori laboratory.
A significant positive correlation (r=0.407, p=0.003) was
observed between 9G4+ IgG serum antibody and HIV neutral-
izing activity (Fig. 5A). Interestingly, anti-dsDNA, ANA, and anti-
CL serum antibodies did not correlate with HIV neutralizing
activity (Fig. 5B–D). The frequency of 9G4+ B cells also positively
correlated (r=0.499, p,0.001) with HIV neutralizing activity
(Fig. 5E). Notably, HIV neutralizing activity also significantly
correlated with HIV VL (r=0.411, p=0.003) (Fig S4) consistent
with previous findings [2,5,7]. These results suggest that BNAb
development may not be caused by an overall breakdown in
tolerance, but rather a more specific subversion of tolerance
mechanisms, evident by the expansion of 9G4+ B cells and
antibodies.
Discussion
This study of ART-negative HIV patients demonstrated
dramatically increased production of 9G4+ IgG serum antibodies
(Fig. 1A) and the in vivo autoreactivity of these 9G4 antibodies as
indicated by their binding to B cells (Fig. 2A+B). This increase
was positively correlated with HIV VL (Fig. 1E). There was also
a significant expansion of 9G4+ memory B cells that had distinct
phenotypes compared with 9G42 memory B cells as indicated by
IgG+ and IgM+ memory B cell populations being over-
represented in the 9G4+ memory compartments (Fig. 2C+D).
A fraction of the 9G4+ serum antibodies and B cells were reactive
to HIV Env (Fig. 3+4), and the abundance of 9G4+ serum
antibodies and B cells positively correlated with serum HIV
neutralizing activity (Fig. 5). These findings demonstrate the
association of autoreactivity with the development of HIV BNAb
at both the cellular level and at the level of serum antibodies.
The presence of 9G4+ IgG serum antibody and 9G4+ memory
B cells is consistent with the impaired B cell tolerance in HIV
patients which has been previously observed, primarily as
autoreactive serum antibodies [8,40,41]. Although the presence
of elevated 9G4+ IgG serum appears to be slightly greater (40%) as
compared to anti-dsDNA, ANA, and CL (15%, 24%, 31%
respectively) in our cohort. Furthermore, we observed a significant
positive correlation between HIV VL and 9G4+ IgG antibody and
9G4+ B cells, but no significant correlation between VL and
Figure 2. Phenotype of 9G4+ B cells in HIV patients. PBMC were incubated at 4uCo r3 7 uC for 30 minutes prior to incubation at 4uC with
antibodies for flow cytometric analysis. A. Representative B cell 9G4 expression profiles. Inset numbers represent frequency of 9G4+ B cells among
total CD19+ B cells. B. 9G4+ B cell frequency for multiple samples; -A, -B, -C, indicate consecutive longitudinal samples from the same HIV patient. C–
E. 9G4+ and 9G42 B cells incubated at 37uC for 30 minutes and then stained for surface markers and phenotypic analysis peformed using indicated
gating strategy (C) to determine composition of total CD19+ total B cell population (D) and IgD2CD19+ memory B cell population (E) determined for
9 samples from unique HIV patients. * p,0.05 (two-tailed paired t-test).
doi:10.1371/journal.pone.0035356.g002
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9G4 induction may be a more selective process induced by the
HIV virus, either directly through viral antigens or indirectly
through the generation of autoantigens known to react with 9G4+
antibodies, such as apoptotic cells [42,43], as opposed to simply
generalized B cell activation which might, at least in part, lead to
the development of other autoreactivities in HIV patients, such as
anti-DNA and anti-CL antibodies. The former possibility is being
currently addressed by the characterization of 9G4 monoclonal
antibodies generated from HIV patients using single-cell method-
ologies, and will additionally enable the assessment of polyreactiv-
ity within the 9G4 compartment. The role of the virus in the
induction of the 9G4 responses could also be clarified in part by
ongoing longitudinal analysis of HIV patients, before and after the
initiation of ART, or starting during acute infection to examine
the initial emergence of the 9G4 response, however, this is beyond
the scope of the current study.
Although 9G4+ B cells shared many phenotypic commonalities
with 9G42 B cells in HIV patients, including their presence in
both naı ¨ve and memory B cell compartments, they were over-
represented in the ‘‘IgM only’’ memory (IgD2IgG2IgM+CD27+)
compartment compared to 9G42 B cells (Fig. 2D). The rare IgM
only memory population, is expanded in patients deficient in
activation-induced cytidine deaminase (AID) [44] and has been
suggested to result from cells exiting prematurely from the GC
reaction before class switching occurs or may be due to the result
of GC-independent B cell development [45,46]. This would be
consistent with the features of 9G4+ B cell regulation, where in
healthy control subjects, they are fully excluded from the GC.
However in HIV patients, some 9G4+ B cells are likely to have
participated fully in GC reactions, as evidenced by IgD2IgG+
9G4+ B cell populations. Other 9G4+ B cells in HIV patients may
still be subject to intrinsic or extrinsic regulation that prevents full
GC participation, as evidenced by the over-representation of the
IgM only memory population within the 9G4+ B cell compart-
ment. It is tantalizing to speculate on properties that may
distinguish 9G4+ IgM only memory vs. 9G4+ IgD2IgM2IgG+
memory B cells, such as degree of autoreactivity, responsiveness to
T cell help or suppression, or capacity to migrate toward
CXCL13. These possibilities will be dissected in future studies.
Additional phenotypic differences in the 9G4+ B cell population
may exist and may be revealed by more comprehensive flow-
cytometric based profiling.
The observation of a higher frequency of 9G4+ cells in the Env-
specific memory B cell population compared with the total
memory population suggests in some HIV patients antigen-specific
9G4+ expansion may be occurring. This observation warrants
further investigation to determine if such patients have unique
features, and to address the possible mechanism of 9G4+ Env-
specific memory B cell expansion. The positive correlation
Figure 3. Detection of 9G4+ gp140-reactive serum antibodies. A. Serum was diluted 1:100 and 9G4+ YU2 gp140-reactive antibody detected
by ELISA. Each symbol represents a unique patient. *p,0.05. B–C. Serum from 3 HIV patients and 1 HC subject was serially diluted and 9G4+ gp140-
reactive (B) and total IgG gp140-reactive (C) antibodies determined, and mean +/2 SEM for assay triplicates presented.
doi:10.1371/journal.pone.0035356.g003
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may reflect a direct contribution of 9G4+ IgG to HIV neutralizing
activity, or it might reflect an immunological environment, in
which HIV infection coincidently favors the expansion of both
species. It is evident that 9G4+ cells and serum antibodies
represent only a minority of the Env-specific repertoire, but it
remains to be determined if 9G4+ Env-specific cells and antibodies
have any distinct properties beyond inherent autoreactivity that
may uniquely impact HIV. Although numerous HIV broadly
neutralizing monoclonal antibodies have been described to date,
none are VH4-34-encoded. This does not preclude their existence
or the potential of 9G4+ B cells and antibodies to contribute
substantially to a protective immune response to HIV. Indeed,
given the reactivity 9G4+ antibodies exhibit for glycoproteins,
including an N-linked N acetyllactosamine determinant on
CD45R/B2220 [26] and the I/I blood group antigen
[27,28,29], reactivity of 9G4+ antibodies to HIV Env may in
part be mediated through interaction with glycosylated epitopes.
Thus, detailed assessment of the 9G4+ serum antibodies for HIV
neutralizing activity and specificity should be pursued in future
studies. The expansion of 9G4 in HIV patients could also result
from the polyclonal B cell activation that is readily observed in
HIV patients, which may result from numerous factors including
direct interaction of HIV and B cells through CD21, DC-SIGN,
TLR7, and TLR9 and also indirectly as a consequence of cytokine
upregulation (e.g. IL4, IL10, IL6, IFNa) and T cell help [47].
This work demonstrates the utility of the 9G4 system in
interrogating autoreactivity at the cellular level in HIV patients,
enabling insight into the development and expansion of auto-
reactive B cells and their relationship to the serum antibody
repertoire. Important future questions include whether autoreac-
tive antibodies are a prerequisite for the development of
a protective HIV humoral response. There are clear examples of
individual BNAbs against HIV that have minimal autoreactivity
(e.g. VRC01) [48], but it is unclear if there is a role for relaxed
tolerance in promoting their development. And although it is likely
that autoreactivity in HIV patients may be in part a consequence
of B cell polyclonal activation, polyclonal activation may also
greatly expand the available repertoire of HIV-specific B cells. For
example, a hyperactive state of global B cell dysregulation and
Figure 4. Identification of 9G4+ gp140-reactive B cells. PBMC were incubated at 37uC for 30 minutes, then stained at 4uC with fluorescently
conjugated gp140 and antibodies. A. Representative flow profile of a HC and HIV sample (HIV040). Plots are gated on live,
CD142CD32CD19+IgD2IgM2p242 B cells. B. The frequency of 9G4+ B cells within the total IgD2 IgM2 B cell subset or gp140+ IgD2IgM2 B
cell subset is indicated.
doi:10.1371/journal.pone.0035356.g004
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weakly to HIV-1 Env to productively respond to this viral antigen,
and give rise to antibody-secreting cells.
The association of autoreactivity and BNAbs also has important
implications for HIV vaccine development – especially if
autoreactivity is indeed a prerequisite for the development of
a subset of immunoglobulin specificities that have the potential to
give rise to BNAbs. Although it may not be feasible to completely
uncouple autoreactivity from BNAb development in a vaccine
setting, it is important to note that autoreactivity does not
necessarily equate to manifestations of chronic autoimmune
pathology, or a definitive pre-disposition to autoimmune disease
development. Several observations support this, including the
development of ‘‘non-pathological’’ autoreactive antibodies during
various viral infections including CMV, HCV, and RSV
[49,50,51]. Consistent with this, a number of investigators have
described autoreactive antibodies in HIV-infected individuals as
‘non-pathogenic’’, based on distinct reactivity profiles [13] or lack
of b2GP1 involvement [52] - as compared with HIV-negative
patients with primary autoimmune diseases. Indeed, autoreactive
antibodies are frequently observed in otherwise normal healthy
individuals, absent of any clinical autoimmune disease manifesta-
tions. Minimally, the association of auto- and HIV- reactivity
warrants detailed examination, which can be facilitated by the
9G4 system, as it may reveal critical cellular and molecular
mechanisms by which the repertoire of potential BNAb specifi-
cities is effectively engaged and stimulated to develop into long-
lived plasma cells conferring sustained protection from HIV
infection.
Supporting Information
Figure S1 Common autoantibodies do not correlate
with HIV viral load. Serum samples from ART-negative HIV
patients were assessed for IgG antibody reactive to ANA, dsDNA,
and CL by ELISA. Plasma VL was determined by PCR at the
same timepoint. Dotted line represents positive/negative cut-off
value. Spearmann correlation indicated, each symbol represents
a unique patient.
(TIFF)
Figure S2 Rarity of 9G4+ B cells in the IgD2 compart-
ment of healthy control subjects. PBMC were analyzed ex
vivo by flow cytometry. A. Representative plots from a HC and
HIV patient gated on total CD19+ B cells. B. The frequency of
9G4+ B cells within the IgD2 compartment. Each symbol
represents a unique patient. * p,0.05 (Mann Whitney test).
(TIF)
Figure 5. 9G4+ serum antibodies and 9G4+ B cells correlate with HIV serum broadly neutralizing activity. HIV neutralizing activity of
serum against a panel of five Tier II isolates was determined by TZMbl assay and geometric mean ID50 presented. Serum IgG reactive to 9G4 (A), ANA
(B), dsDNA (C) and cardiolipin (D) was determined by ELISA. E. The frequency of 9G4+ B cells was determined by flow cytometry. Spearmann
correlation indicated. Each symbol represents a unique patient.
doi:10.1371/journal.pone.0035356.g005
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memory B cells. PBMC were obtained from three HIV
patients and IgG+ B cells were isolated and cultured with
CpG+IL-2 for 4 days for the generation of antibody-secreting
cells. EliSpots were performed to identify total IgG, total 9G4,
total IgG gp140, and 9G4+ gp140 specific antibody-secreting cells.
EliSpot coating/detection antibody combinations indicated.
(TIF)
Figure S4 Correlation of HIV serum broadly neutraliz-
ing activity and viral load. HIV neutralizing activity of serum
against a panel of five Tier II isolates was determined by TZMbl
assay and geometric mean ID50 presented with HIV VL.
Spearmann correlation indicated, each symbol represents a unique
patient.
(TIFF)
Table S1 HIV serum neutralizing activity. A. Clade B
serum neutralizing activity B. Multi-clade serum neutralizing
activity.
(PDF)
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